Business Context and Reporting Period
Company: Chemed Corporation
Filing Type: Form 8-K (Current Report)
Date of Report: November 30, 1994
Event: Sale of a significant portion of the company's investment in Omnicare, Inc., a publicly-traded affiliate.
Key Financial Metrics
Transaction Details:
- Shares Sold: 1,570,000 shares of Omnicare, Inc. common stock.
- Sale Price: $37.82 per share (net of underwriting discounts and commissions).
- Total Proceeds: $59.4 million.
- After-Tax Gain: Approximately $21 million.
- Remaining Interest: 727,000 shares (5.8% ownership).
- Total Sales and Service Revenues: $479,542,000 (Unchanged from historical).
- Income from Continuing Operations: $11,219,000 (Pro Forma) vs. $14,981,000 (Historical).
- Earnings Per Share (Continuing Operations): $1.14 (Pro Forma) vs. $1.52 (Historical).
- Total Assets: $532,744,000 (Pro Forma) vs. $481,771,000 (Historical).
- Long-Term Debt: Reduced by $10 million to $98,072,000 (Pro Forma).
- Cash and Cash Equivalents: Increased to $65,270,000 (Pro Forma).
- Income from Continuing Operations: $14,951,000 (Pro Forma) vs. $17,142,000 (Historical).
- Earnings Per Share (Continuing Operations): $1.53 (Pro Forma) vs. $1.75 (Historical).
Material Changes Versus Prior Period
The filing presents unaudited pro forma financial information to reflect the sale of Omnicare stock as if it occurred at the beginning of the periods presented. Key changes include:
- Reclassification: Equity in earnings of Omnicare and previously recognized gains on dispositions have been reclassified to "discontinued operations."
- Debt Reduction: Pro forma adjustments assume $10 million of proceeds were used to reduce borrowings, resulting in a pretax interest expense reduction of $384,000 for the nine-month period.
- Asset Valuation: The remaining investment in Omnicare (727,000 shares) was marked to market value ($40.125 per share) in accordance with SFAS No. 115, increasing the value of "Other investments" and "Unrealized appreciation on investments."
- EPS Impact: Pro forma EPS for continuing operations decreased for both the nine-month 1994 period and the full year 1993 due to the removal of Omnicare equity earnings from continuing operations.
Guidance, Outlook, and Risks
Management Commentary:
The filing focuses on the mechanics of the divestiture and the resulting pro forma financial position. Management utilized the proceeds to reduce debt, specifically targeting revolving credit and term loan agreements.
Accounting Adjustments:
- The effective tax rate on the sale exceeded the statutory 34% rate due to a lower tax basis versus book basis of the investment.
- Dividend income from the remaining Omnicare shares is now recognized as "Other income, net" rather than equity earnings.
Risks and Contingencies:
The filing does not explicitly list new risks or contingencies beyond the standard disclosure of the transaction terms and the reliance on Omnicare's prospectus for pricing principles.
Investor Verification Checklist
- Transaction Finality: Confirm the closing of the 1,570,000 share sale and the receipt of $59.4 million in net proceeds.
- Debt Reduction: Verify the actual application of proceeds toward the $10 million debt reduction and the resulting interest savings.
- Remaining Stake: Monitor the performance of the remaining 5.8% Omnicare stake, now valued at market price rather than equity method.
- Discontinued Operations: Review future 10-Q and 10-K filings to ensure Omnicare-related earnings are correctly segregated into discontinued operations.
- Pro Forma Accuracy: Compare actual future financial results against the pro forma assumptions regarding interest expense and dividend income.